Treatment for Anemia, Sickle Cell

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Anemia, Sickle Cell+6 More
Eligibility
< 65
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test a new app to help people with sickle cell disease take their medication as prescribed. The goal is to improve health outcomes for these patients.

Eligible Conditions
  • Anemia, Sickle Cell
  • Sickle Cell Hemoglobin C
  • Sickle B+ Thalassemia
  • Thalassemia

Treatment Effectiveness

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 12 weeks

12 weeks
Hydroxyurea adherence rates
Percentage of patients achieving feasibility criteria of using the MED-Go app
Scores of System Usability Scale (SUS)

Trial Safety

Trial Design

1 Treatment Group

Control Arm
1 of 1

Active Control

40 Total Participants · 1 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Control ArmNoIntervention Group · 1 Intervention: Control Arm · Intervention Types:

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 12 weeks

Who is running the clinical trial?

National Heart, Lung, and Blood Institute (NHLBI)NIH
3,577 Previous Clinical Trials
46,968,550 Total Patients Enrolled
149 Trials studying Anemia, Sickle Cell
46,387 Patients Enrolled for Anemia, Sickle Cell
Ann & Robert H Lurie Children's Hospital of ChicagoLead Sponsor
230 Previous Clinical Trials
5,178,351 Total Patients Enrolled
10 Trials studying Anemia, Sickle Cell
651 Patients Enrolled for Anemia, Sickle Cell
Sherif M. Badawy, MD, MSPrincipal InvestigatorAnn & Robert H Lurie Children's Hospital of Chicago
2 Previous Clinical Trials
105 Total Patients Enrolled
2 Trials studying Anemia, Sickle Cell
105 Patients Enrolled for Anemia, Sickle Cell

Eligibility Criteria

Age < 65 · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 23rd, 2021

Last Reviewed: November 26th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.